Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus

Regulatory and Implementation Considerations for Artificial Intelligence

Successful artificial intelligence (AI) implementation is predicated on the trust of clinicians and patients, and is achieved through a culture of responsible use, focusing on regulations, standards, and education. Otolaryngologists can overcome barriers in AI implementation by promoting data standardization through professional societies, engaging in institutional efforts to integrate AI, and developing otolaryngology-specific AI education for both trainees and practitioners.

Artificial Intelligence and Ophthalmic Clinical Registries

PURPOSE

The recent advances in artificial intelligence (AI) represent a promising solution to increasing clinical demand and ever limited health resources. Whilst powerful, AI models require vast amounts of representative training data to output meaningful predictions in the clinical environment. Clinical registries represent a promising source of large volume real-world data which could be used to train more accurate and widely applicable AI models. This review aims to provide an overview of the current applications of AI to ophthalmic clinical registry data.

DESIGN AND METHODS

A systematic search of EMBASE, Medline, PubMed, Scopus and Web of Science for primary research articles that applied AI to ophthalmic clinical registry data was conducted in July 2024.

RESULTS

Twenty-three primary research articles applying AI to ophthalmic clinic registries (n = 14) were found. Registries were primarily defined by the condition captured and the most common conditions where AI was applied were glaucoma (n = 3) and neovascular age-related macular degeneration (n = 3). Tabular clinical data was the most common form of input into AI algorithms and outputs were primarily classifiers (n = 8, 40%) and risk quantifier models (n = 7, 35%). The AI algorithms applied were almost exclusively supervised conventional machine learning models (n = 39, 85%) such as decision tree classifiers and logistic regression, with only 7 applications of deep learning or natural language processing algorithms. Significant heterogeneity was found with regards to model validation methodology and measures of performance.

CONCLUSIONS

Limited applications of deep learning algorithms to clinical registry data have been reported. The lack of standardized validation methodology and heterogeneity of performance outcome reporting suggests that the application of AI to clinical registries is still in its infancy constrained by the poor accessibility of registry data and reflecting the need for a standardization of methodology and greater involvement of domain experts in the future development of clinically deployable AI.

Artificial intelligence for diabetes care: current and future prospects

Artificial intelligence (AI) use in diabetes care is increasingly being explored to personalise care for people with diabetes and adapt treatments for complex presentations. However, the rapid advancement of AI also introduces challenges such as potential biases, ethical considerations, and implementation challenges in ensuring that its deployment is equitable. Ensuring inclusive and ethical developments of AI technology can empower both health-care providers and people with diabetes in managing the condition. In this Review, we explore and summarise the current and future prospects of AI across the diabetes care continuum, from enhancing screening and diagnosis to optimising treatment and predicting and managing complications.

Advances in Structural and Functional Retinal Imaging and Biomarkers for Early Detection of Diabetic Retinopathy

Diabetic retinopathy (DR), a vision-threatening microvascular complication of diabetes mellitus (DM), is a leading cause of blindness worldwide that requires early detection and intervention. However, diagnosing DR early remains challenging due to the subtle nature of initial pathological changes. This review explores developments in multimodal imaging and functional tests for early DR detection. Where conventional color fundus photography is limited in the field of view and resolution, advanced quantitative analysis of retinal vessel traits such as retinal microvascular caliber, tortuosity, and fractal dimension (FD) can provide additional prognostic value. Optical coherence tomography (OCT) has also emerged as a reliable structural imaging tool for assessing retinal and choroidal neurodegenerative changes, which show potential as early DR biomarkers. Optical coherence tomography angiography (OCTA) enables the evaluation of vascular perfusion and the contours of the foveal avascular zone (FAZ), providing valuable insights into early retinal and choroidal vascular changes. Functional tests, including multifocal electroretinography (mfERG), visual evoked potential (VEP), multifocal pupillographic objective perimetry (mfPOP), microperimetry, and contrast sensitivity (CS), offer complementary data on early functional deficits in DR. More importantly, combining structural and functional imaging data may facilitate earlier detection of DR and targeted management strategies based on disease progression. Artificial intelligence (AI) techniques show promise for automated lesion detection, risk stratification, and biomarker discovery from various imaging data. Additionally, hematological parameters, such as neutrophil-lymphocyte ratio (NLR) and neutrophil extracellular traps (NETs), may be useful in predicting DR risk and progression. Although current methods can detect early DR, there is still a need for further research and development of reliable, cost-effective methods for large-scale screening and monitoring of individuals with DM.

Prognostic potentials of AI in ophthalmology: systemic disease forecasting via retinal imaging

BACKGROUND

Artificial intelligence (AI) that utilizes deep learning (DL) has potential for systemic disease prediction using retinal imaging. The retina's unique features enable non-invasive visualization of the central nervous system and microvascular circulation, aiding early detection and personalized treatment plans for personalized care. This review explores the value of retinal assessment, AI-based retinal biomarkers, and the importance of longitudinal prediction models in personalized care.

MAIN TEXT

This narrative review extensively surveys the literature for relevant studies in PubMed and Google Scholar, investigating the application of AI-based retina biomarkers in predicting systemic diseases using retinal fundus photography. The study settings, sample sizes, utilized AI models and corresponding results were extracted and analysed. This review highlights the substantial potential of AI-based retinal biomarkers in predicting neurodegenerative, cardiovascular, and chronic kidney diseases. Notably, DL algorithms have demonstrated effectiveness in identifying retinal image features associated with cognitive decline, dementia, Parkinson's disease, and cardiovascular risk factors. Furthermore, longitudinal prediction models leveraging retinal images have shown potential in continuous disease risk assessment and early detection. AI-based retinal biomarkers are non-invasive, accurate, and efficient for disease forecasting and personalized care.

CONCLUSION

AI-based retinal imaging hold promise in transforming primary care and systemic disease management. Together, the retina's unique features and the power of AI enable early detection, risk stratification, and help revolutionizing disease management plans. However, to fully realize the potential of AI in this domain, further research and validation in real-world settings are essential.

Challenges of artificial intelligence in medicine and dermatology

Artificial intelligence (AI) in medicine and dermatology brings additional challenges related to bias, transparency, ethics, security, and inequality. Bias in AI algorithms can arise from biased training data or decision-making processes, leading to disparities in health care outcomes. Addressing bias requires careful examination of the data used to train AI models and implementation of strategies to mitigate bias during algorithm development. Transparency is another critical challenge, as AI systems often operate as black boxes, making it difficult to understand how decisions are reached. Ensuring transparency in AI algorithms is vital to gaining trust from both patients and health care providers. Ethical considerations arise when using AI in health care, including issues such as informed consent, privacy, and the responsibility for the decisions made by AI systems. It is essential to establish clear guidelines and frameworks that govern the ethical use of AI, including maintaining patient autonomy and protecting sensitive health information. Security is a significant concern in AI systems, as they rely on vast amounts of sensitive patient data. Protecting these data from unauthorized access, breaches, or malicious attacks is paramount to maintaining patient privacy and trust in AI technologies. Lastly, the potential for inequality arises if AI technologies are not accessible to all populations, leading to a digital divide in health care. Efforts should be made to ensure that AI solutions are affordable, accessible, and tailored to the needs of diverse communities, mitigating the risk of exacerbating existing health care disparities. Addressing these challenges is crucial for AI's responsible and equitable integration in medicine and dermatology.